{"type":"trials","record":{"id":41676,"source_id":"clinicaltrials-gov","external_id":"NCT06952452","title":"Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)","brief_summary":"This is a phase III, multicenter, randomized double-blinded clinical trial with two parallel groups (ranibizumab and bevacizumab) and an observational follow-up of patients who meet elegibility criteria and decline participation due to treatment randomization. It will be performed involving 630 eyes from patients with wet age-related macular degeneration (wAMD) diagnosis without another eye disease. This clinical trial compares the treatment response for 3 years, considering genetic variants already studied between the eyes treated with one of the first options of anti-VEGF used in patients with wAMD, (ranibizumab) and the most cost-effective anti-VEGF (bevacizumab; off-label use)","overall_status":"Recruiting","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Parc de Salut Mar","enrollment":630,"countries":["Spain"],"start_date":"2022-11-18","completion_date":"2026-07-01","last_update_date":"2025-11-20","source_url":"https://clinicaltrials.gov/study/NCT06952452","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"AMD","age_range":"50 Years","comparator":"Ranibizumab, RBZ (group B)","organization":"Parc de Salut Mar","interventions":["Bevacizumab","Ranibizumab Ophthalmic"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Frequency of Genetic Polymorphism in VEGFA Associated With Anti-VEGF Treatment Response in AMD Patients — From baseline…","Change in Visual Acuity Over Time in Patients With AMD Receiving Anti-VEGF Therapy — Baseline, 6 months, 12 months, 24…","Change in Retinal Fluid and Foveal Thickness Over Time as Measured by OCT in Patients With AMD Treated With Anti-VEGF T…","Distribution of Sex Among Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Distribution of Age at Diagnosis in Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Proportion of Smokers Among Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Weight of Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Height of Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Prevalence of Obesity in Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Prevalence of Hypertension in Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Number of Participants With Ocular and Systemic Adverse Events Associated With Intravitreal Anti-VEGF Therapy — From in…","Total Direct Healthcare Cost per Patient for Anti-VEGF Therapy Over One Year From the Health System Perspective — From…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration","Bevacizumab","Ranibizumab Ophthalmic"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06952452","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-11-18 to 2026-07-01","comparator":"Ranibizumab, RBZ (group B)","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.852Z","intervention":["Bevacizumab","Ranibizumab Ophthalmic"],"participants":630,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Frequency of Genetic Polymorphism in VEGFA Associated With Anti-VEGF Treatment Response in AMD Patients — From baseline…","Change in Visual Acuity Over Time in Patients With AMD Receiving Anti-VEGF Therapy — Baseline, 6 months, 12 months, 24…","Change in Retinal Fluid and Foveal Thickness Over Time as Measured by OCT in Patients With AMD Treated With Anti-VEGF T…","Distribution of Sex Among Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Distribution of Age at Diagnosis in Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Proportion of Smokers Among Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Weight of Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Height of Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Prevalence of Obesity in Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Prevalence of Hypertension in Patients With AMD Receiving Anti-VEGF Therapy — At baseline","Number of Participants With Ocular and Systemic Adverse Events Associated With Intravitreal Anti-VEGF Therapy — From in…","Total Direct Healthcare Cost per Patient for Anti-VEGF Therapy Over One Year From the Health System Perspective — From…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41676","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}